Genetic Technologies Limited · ASX:GTG
Genetic Technologies — Shareholder Meeting (November 2004)
48 slides from Genetic Technologies's shareholder meeting presentation, Nov 25, 2004
Slide 1: Presentation by Dr. Mervyn Jacobson, Executive Chairman
Presentation by Dr. Mervyn Jacobson, Executive Chairman to the Annual General Meeting of Genetic Technologies Limited (“GTG”), Melbourne, November 25th, 2004 Introduction « Avery warm welcome to all present, to this 2004 Annual Meeting of Shareholders of GTG. « My name is Dr. Mervyn Jacobson, and |
Slide 2: Building the GTG Infrastructure
Building the GTG Infrastructure. Last year, | made the observation that, as GTG grew, we were identifying more and more new opportunities in the world of biotech, and that we had to focus on the future — to “seize the day” and become a leader in the biotech space — and accordingly, the time had come
Slide 3: Building on Current Opportunities
Building on Current Opportunities: « Service Testing * Deon has already described this growing opportunity. e Again, what began originally as just disputed paternity has since grown - to include other human genes, and now forensics, and also animals and plants. »* And what began just in Australia is
Slide 4: Pursuing New Strategic Opportunities
Pursuing New Strategic Opportunities « Global Our service testing, licensing, and research activities are becoming internationalised. We are now coming to the attention of various global players — companies with revenues of several billions per year, and market caps of tens of billions are now wanti
Slide 5: Creating True Value for our Shareholders
Creating True Value for our Shareholders. We have seen our shareholder base grow from 1,200, to 2,500, to 4,500, and now — to over 5,000 shareholders. These shareholders are supporting our vision - and we are determined to do what we can to steadily build the long term value of their investment. « C
Slide 6: Protecting our Patents
Protecting our Patents « ALRC * According to certain media reports, the impression could be gained that ALRC was set up just to control GTG. e Infact, ALRC was set up well before we had our first sensational coverage on “60 Minutes”, then “Four Corners”, then Forbes magazine, etc, as we discussed la
Slide 7: In Summary
In Summary: « GTG wish to be world-class in all we do. « Seek to excel « New technology « Appreciation of shareholder value « Giving some thing back Finally - a special thanks to all our staff, collaborators, consultants and stockholders who have enthusiastically supported our vision for GTG over th
Slide 8: of
Genetic Technologies Presentation 25/11/04 4 of 41
Slide 9: Professor Deon Venter
Genetic Technologies Presentation 25/11/04 2 of 41 Professor Deon Venter Director Genetic Testing
Slide 10: Genetic testing network
Genetic Technologies Presentation 25/11/04 3 of 41 eg Bonomic PUBIC Sholay ng Beovction Bi TAG NEIWORK: HUMAN DNA AESUING LABORATORY WAJOn PATHOLOGY ROUIDE RL eae GINLICS FRU OERS nals Mas ebay
Slide 11: Ae Ue
Genetic Technologies Presentation 25/11/04 4 of 41 Ae Ue — ay ye ee Ly, Ly / Le ae LU es : J, LZ, es 7 ae oe ZL ee a Ue a TET PE a J yO Q LE Gg ae ge citi La 7 j 7 MG ee NES Ey g ae
Slide 12: TEE
Genetic Technologies Presentation 25/11/04 5 of 41 TEE TE a ge yy He ws ae cnn ee yy) Laas
Slide 13: Qualification of Leads
Genetic Technologies Presentation 25/11/04 6 of 41 LL ee a lificalion of Leads 4 oie ao Lie yy ee Ly y a Daas 7, ANGE eZ L 5 ae y Ce iy
Slide 14: Upfront licence fee
Genetic Technologies Presentation 25/11/04 7 of 44 Uptira thicence Fee aa nnn 0) ee ae Le ee a MINN eee UU ee eat Lil GUI mal se Dee oe ee La) a
Slide 15: of
Genetic Technologies Presentation 25/11/04 8 of 41
Slide 16: Types of Licence
Genetic Technologies Presentation 25/11/04 9 of 44 By a i ay Typesof cence ss (qq i i ence A ee es rains Ne Sn cNNNIT 8 Lg)
Slide 17: nile
Genetic Technologies Presentation 25/11/04 10 of 44 a nile i, ip lee Saini 2 i icer a ST ae Ue tee vo ye
Slide 18: it of
Genetic Technologies Presentation 25/11/04 it of 44
Slide 19: RareCellect
Genetic Technologies Presentation 25/11/04 12 of 44 - RareCellect Research lin major phar Issued worldwide patents and two « alent applications
Slide 20: Foetal Cell Separation
Genetic Technologies Presentation 25/11/04 13 of 44 Foetal Cell Sepa i a: *
Slide 21: iin ae y
Genetic Technologies Presentation 25/11/04 14 of 44 iin ae y
Slide 22: Lee
Genetic Technologies Presentation 25/11/04 15 of 44 oo. Lee no ea reall ee si: ee Co o ie 7 a a iG Ce
Slide 23: ba tintin
Genetic Technologies Presentation 25/11/04 16 of 44 LC ba tintin of ae y a
Slide 24: Candidate diagnostic DNA sequences
Genetic Technologies Presentation 25/11/04 i7 of 44 ed DNA sequen ee Candidate: diag lan , . ah ) ie ie Va ae Co
Slide 25: Sue Lang
Genetic Technologies Presentation 25/11/04 18 of 44 sue Lang Media and Marketing Manager Marketing and Media
Slide 26: Marketing
Genetic Technologies Presentation 25/11/04 19 of 44 arketing Vou have a great new PrOMuGi se re now whaldo you dor * Development GIG marketing and communicalion plan * Specific product/service based plans * Gradual integration under GIG parent orand
Slide 27: Established media contact database
Genetic Technologies Presentation 25/11/04 20 of 44 Established media contact dalabace Developi ips it) science, medical umnalis i systems - Alows quicker response Proactive approach Good coverage to date
Slide 28: Genetic test for epilepsy
Genetic Technologies Presentation 25/1 1104 21 of 44 Genetic test | ‘for epilepsy |} a hy SRL SReGacuieraie aosbait way: 1 eh totes ne aoneeer Tete foun, Peeling in mice uli Seve a ce at ether, ny init, ee, jee bere deach wre ahap ber Ee et “al He ata te Shllieart wins showy “ay i ay, er i a A ng le
Slide 29: Financial Overview
Genetic Technologies Presentation 25/11/04 22 of 44 Financial Overview
Slide 30: of
Genetic Technologies Presentation 25/11/04 23 of 44
Slide 31: ANT
Genetic Technologies Presentation 25/11/04 24 of 44 ANT TA ANNA ge NI III AGH ACME SLANT SA
Slide 32: OUI
Genetic Technologies Presentation 25/11/04 25 of 44 OUI ie
Slide 33: NASDAQ listing nearing completion
Genetic Technologies Presentation 25/11/04 26 of 44 (Level 2) nearing completion ne expected to occur early in 2005 NASOAC listing will provide ve éxposilre and enables qrester access for Slors
Slide 34: of
Genetic Technologies Presentation 25/11/04 27 of 44
Slide 35: of
Genetic Technologies Presentation 25/11/04 28 of 44
Slide 36: Research
Genetic Technologies Presentation 25/11/04 29 of 44 * Research
Slide 37: of ee a Oo a a a a ee ee A a : a
Genetic Technologies Presentation 25/11/04 30 of 41 ee a Oo a a a a ee ee A a : a
Slide 38: Creating True Value for our Shareholders
Genetic Technologies Presentation 25/11/04 31 of 41 ae Creating True Value f o : Pursuing u * Completing NAS - Pursuing investor corporate develop
Slide 39: Protecting Our Patents
Genetic Technologies Presentation 25/11/04 32 of 41 a “Protecting O' P. Various | . Applera
Slide 40: In Summary
Genetic Technologies Presentation 25/11/04 33 of 44 ea -inSummary a, orking to achieve arenolder val
Slide 41: of il iy
Genetic Technologies Presentation 25/11/04 34 of 41 il iy
Slide 42: of
Genetic Technologies Presentation 25/11/04 35 of 41
Slide 43: of | Lien
Genetic Technologies Presentation 25/11/04 36 of 41 4 | Lien
Slide 44: eo a Sean
Genetic Technologies Presentation 25/11/04 37 of 44 eo a Sean Lo ; A ee ey Enchrgered
Slide 45: of
Genetic Technologies Presentation 25/11/04 38 of 41
Slide 46: oor ii
Genetic Technologies Presentation 25/11/04 39 of 41 a oor ii
Slide 47: ia inh
Genetic Technologies Presentation 25/11/04 40 of 44 ia inh eC Reintradu planning unde
Slide 48: Questions from the floor
Genetic Technologies Presentation 25/11/04 Al of 44 Questions from the
Genetic Technologies — Shareholder Meeting (November 2004) on 6ix